ProCap Financial’s Feeding Frenzy Continues with Additional Share Repurchases

• ProCap Financial repurchased 196,043 shares on Thursday, March 5, 2026
• Company remains committed to aggressively repurchasing shares at a significant discount to NAV

NEW YORK--(BUSINESS WIRE)-- ProCap Financial, Inc. (Nasdaq: BRR), the first publicly traded agentic finance firm, today announced it repurchased 196,043 shares of its common stock in the open market yesterday.

"We loaded up our shopping cart today with BRR shares,” said Anthony Pompliano, Chairman and CEO of ProCap Financial. “The market is being irrational and we are capitalizing on it."

ProCap Financial will continue aggressively repurchasing shares at a significant discount to NAV. Going forward, the Company will announce share buyback activity periodically rather than daily.

About ProCap Financial
ProCap Financial is the first publicly traded agentic finance firm. The Company’s mission is to help independent investors make money. Founded in 2025, the Company raised more than $750 million from leading investors and is traded on Nasdaq under the symbol BRR. Visit www.procapfinancial.com for more information.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially. Such risks include those described under “Risk Factors” in most recent SEC filings. We caution readers not to place undue reliance on forward-looking statements, which reflect our views only as of the date of this release. We undertake no obligation to update such statements, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260306339394/en/

MEDIA CONTACT
Erica Chase
[email protected]

INVESTOR CONTACT
[email protected]

Source: ProCap Financial, Inc.

You May Also Be Interested In

• Light & Wonder to report Q2 results Aug. 4, reaffirms FY26 outlook
• WISeKey reports 115% revenue rise in H1 2026, reaffirms FY outlook
• Mesoblast reaches 300-patient enrollment in back pain Phase 3 trial